Effect of a Protein-Creatine-Omega3-Vitamin D Supplement on Glycemic Variability in Mexican Patients With Type 2 Diabetes

NANot yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

June 1, 2025

Primary Completion Date

May 1, 2026

Study Completion Date

October 25, 2026

Conditions
Type 2 Diabetes Mellitus
Interventions
DIETARY_SUPPLEMENT

Protein-Creatine-Omega-3-Vitamin D Supplement

Participants will receive a daily powdered supplement containing 30 g of whey protein isolate, 5 g of creatine monohydrate, 1 g of omega-3 fatty acids (EPA/DHA), and 1,000 IU of vitamin D3. The supplement will be taken once daily for 12 weeks, dissolved in water. It is designed to reduce glycemic variability and improve metabolic parameters in individuals with recently diagnosed type 2 diabetes.

DIETARY_SUPPLEMENT

Placebo (Maltodextrin)

Participants will receive a daily powdered placebo formulated with maltodextrin, without any active ingredients (no whey protein, creatine, omega-3, or vitamin D). It is identical in appearance, taste, and packaging to the active supplement. It will be taken once daily for 12 weeks and administered in the same conditions as the intervention group.

All Listed Sponsors
collaborator

University of Illinois at Chicago

OTHER

lead

Héctor Iván Saldívar Cerón

OTHER